Pacira Pharmaceuticals Inc (PCRX)

Payables turnover

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cost of revenue	US$ in thousands	184,669	199,295	140,255	117,328	106,712
Payables	US$ in thousands	15,698	15,220	10,543	10,431	12,799
Payables turnover		11.76	13.09	13.30	11.25	8.34

December 31, 2023 calculation

Payables turnover = Cost of revenue ÷ Payables
= $184,669K ÷ $15,698K
= 11.76

Pacira BioSciences Inc's payables turnover has shown consistency and improvement over the past five years. The ratio has displayed an upward trend, indicating the company is managing its accounts payable more efficiently. The higher payables turnover ratios in recent years suggest that Pacira is taking less time to pay off its suppliers and vendors. This could be beneficial in terms of maintaining good relationships with suppliers, managing working capital effectively, and potentially negotiating better credit terms. Overall, the increasing trend in payables turnover reflects positively on Pacira's financial management and liquidity position.